268 drugs removed from medical insurance (list attached)

On January 6, Shandong provincial drug centralized purchase network released the notice on adjusting the medical insurance attributes of online products by drug purchase platform of provincial public resource trading center According to the notice, since January 1, 2020, Shandong basic medical insurance, work-related injury insurance and maternity insurance will implement the new version of the national directory of basic medical insurance, work-related injury insurance and maternity insurance drugs, and the adjustment of the medical insurance ownership of online products on the drug purchase platform of the provincial public resource trading center has ended With the implementation of the new version of the national medical insurance catalog, a large number of drugs ushered in great changes According to the notice on the implementation of the new version of the national basic medical insurance, industrial injury insurance and maternity insurance drug catalogue issued by Shandong Medical Insurance Bureau recently: The western medicine and Chinese patent medicine in the catalogue of drugs for work-related injury insurance and maternity insurance of Shandong Province (2017 Edition) have been included in the new version of the National Drug Catalogue according to the national regulations; those not included in the new version of the National Drug Catalogue shall be temporarily implemented according to the original regulations, and the provincial medical insurance bureau will gradually digest them according to the relevant requirements and procedures within three years In the digestion process, priority should be given to adjusting the payment scope of drugs included in the national key monitoring scope Shandong Medical Insurance Bureau has announced 268 medical insurance varieties gradually digested in three years, including 143 Western medicines and 125 Chinese patent medicines (see the end of the article for the detailed list of varieties) In fact, with the implementation of the new version of the national medical insurance catalogue on January 1, the gradual digestion of local supplementary varieties within three years is also officially put on the agenda The next three years are the deadline for the original supplementary varieties These varieties may face two fates: one is to successfully enter the national medical insurance catalog during the dynamic adjustment of the medical insurance catalog during this period; the other is to be completely kicked out of the scope of medical insurance and become self financed varieties Once these varieties are removed from the medical insurance catalog, the impact on drug companies is very huge Some pharmaceutical companies said that many local supplement varieties rely on entering the local supplement catalogue to support product sales Without access to the national health insurance before being digested, the market of some products may face a devastating blow In particular, the regulation of giving priority to the transfer out of national key monitored varieties has made clear the priority of transfer out, and about 300 pharmaceutical enterprises will face severe challenges According to the regulations of Shandong Medical Insurance Bureau, the Chinese patent medicine and Chinese Herbal Pieces in the new version of the national drug Catalog shall be prescribed by qualified doctors, and the fund can be paid according to the regulations Each overall planning area should further strengthen the examination and approval management of doctors' prescription qualification by establishing and improving the medical insurance agreement doctor system Previously, only the western medicine that meets the requirements of the national health and health commission can issue the prescription of Chinese patent medicine Now, the medical insurance bureau has also made clear provisions on this requirement, and restricted the western medicine that does not meet the requirements from the source of medical insurance fund, which has a further promoting role in restricting the rational use of Chinese patent medicine by doctors At the same time, it is a more serious challenge for Chinese medicine enterprises It was originally from the level of assessing doctors and hospitals Western medicine that did not meet the requirements could not prescribe traditional Chinese medicine This was from the level of doctors At present, it is directly limited in the medical insurance system The prescription of Chinese patent medicine issued by western medicine that does not meet the requirements cannot be reimbursed This is from the patient level Under the combination of the two, fighting for the prescription right of qualified doctors has become another white hot battlefield of traditional Chinese medicine enterprises.